VC fund profile · evidence-aware directory data
F-Prime Capital stages, portfolio and investment profile
Cambridge-based venture firm affiliated with Fidelity Investments, with a heritage tracing to Fidelity's venture arm. Self-capitalized investor in life sciences, healthtech, enterprise software, fintech, and frontier technology across North America and Europe.
Keep track of F-Prime Capital
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$1M–$10M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Series A, Series B+
Participates: Seed, Series A, Series B+
Sector focus
healthtech · biotech-life-sciences
Geography
Cambridge, MA
Founded 2016
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
8
Linked startup profiles
Latest fund vehicle
Not recorded
Vehicle name, size, and vintage are not yet structured.
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Portfolio companies we track
Startups in our directory that list F-Prime Capital as an investor (8 total).
- Arboretum LifeSciences Molecular-information company expanding genetic testing and precision medicine into common diseases.
- BioAge Labs Clinical-stage biotech targeting metabolic disease and aging biology (public: BIOA).
- Firefly Health Virtual-first primary care and employer health-plan platform.
- Method Embedded API linking consumer debt accounts for repayment and balance transfers.
- Nava Therapeutics Biotech developing next-generation lipid nanoparticle (LNP) delivery systems.
- PatientPing National ADT care-coordination network, now part of Bamboo Health after Appriss Health acquisition.
- R1 Therapeutics Clinical-stage kidney-disease therapeutics company developing AP306
- Zus Health Shared health data platform giving digital health builders a common patient record (ZAP).
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.